Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...

In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts. Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention. This ...

Orphan drug status adds regulatory incentives and boosts visibility for IFx-2.0. ・Early trial data showed the treatment was ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

With the stock market charging higher in 2025, a group of small-cap stocks has presented unique and focused opportunities for investors. These companies have more than doubled in the past few months, ...

Small caps continue to have attractive valuations heading into 2026. Compared to large caps on a relative basis, small caps are significantly cheaper today than they were in most time periods. It is ...

Investing.com -- The biotechnology sector continues to offer compelling investment opportunities in 2026, with several companies poised for significant growth according to Bank of America analysts.

Despite facing near-term financial pressures, the healthcare sector’s growth prospects for 2026 remain optimistic, fueled by demographic tailwinds and therapeutic innovation. For investors looking ...